These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 10715949)
21. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia. Singla R; Al-Sharif N; Al-Sayegh MO; Osman MM; Shaikh MA Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297 [TBL] [Abstract][Full Text] [Related]
22. XDR-TB: entering the post-antibiotic era? Raviglione M Int J Tuberc Lung Dis; 2006 Nov; 10(11):1185-7. PubMed ID: 17131774 [No Abstract] [Full Text] [Related]
23. [Clinical value of microchip technology in determination of drug resistance of Mycobacterium tuberculosis]. Vasil'eva IA; Chernousova LN; Zasedatelev AS; Sobolev AIu; Mikhaĭlovich VM Probl Tuberk; 2002; (6):21-4. PubMed ID: 12227044 [TBL] [Abstract][Full Text] [Related]
24. [Effectiveness of the surgical treatment of patients with pulmonary tuberculosis and multidrug resistance of its causative agent]. Shaĭkhaev AIa; Naumov VN Probl Tuberk; 2000; (4):24-6. PubMed ID: 10981427 [TBL] [Abstract][Full Text] [Related]
25. Rifamycin treatment of tuberculosis in a patient receiving atenolol: less interaction with rifabutin than with rifampin. Goldberg SV; Hanson D; Peloquin CA Clin Infect Dis; 2003 Aug; 37(4):607-8. PubMed ID: 12905149 [No Abstract] [Full Text] [Related]
26. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis. Figueiredo R; Moiteiro C; Medeiros MA; da Silva PA; Ramos D; Spies F; Ribeiro MO; Lourenço MC; Júnior IN; Gaspar MM; Cruz ME; Curto MJ; Franzblau SG; Orozco H; Aguilar D; Hernandez-Pando R; Costa MC Bioorg Med Chem; 2009 Jan; 17(2):503-11. PubMed ID: 19119013 [TBL] [Abstract][Full Text] [Related]
27. [Analysis of risk factors of the occurrence of drug resistance in patients with tuberculosis from civil and penitentiary sectors in the Samara Region]. Balabanova IaM; Raddi M; Gram K; Malomanova NA; Elizarova ED; Kuznetsov SI; Gusarova GI; Zakharova SM; Melent'ev AS; Kriukova EG; Fedorin IM; Golyshevskaia VI; Dorozhkova IR; Shilova MV; Erokhin VV; Drobnevskiĭ F Probl Tuberk Bolezn Legk; 2005; (5):25-31. PubMed ID: 15988974 [TBL] [Abstract][Full Text] [Related]
28. Multidrug resistant tuberculosis in a 6 year old child. Suessmuth S; Bange FC; Gappa M Paediatr Respir Rev; 2007 Sep; 8(3):265-8. PubMed ID: 17868926 [TBL] [Abstract][Full Text] [Related]
29. [Rifabutin. An antibiotic against mycobacteria]. Andersen AB Ugeskr Laeger; 1997 Nov; 159(46):6844-8. PubMed ID: 9412003 [No Abstract] [Full Text] [Related]
30. [Drug-resistant pulmonary tuberculosis at the penitentiaries]. Kononets AS Probl Tuberk Bolezn Legk; 2008; (12):60-3. PubMed ID: 19227326 [TBL] [Abstract][Full Text] [Related]
31. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months. Nolan CM; Goldberg SV Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140 [TBL] [Abstract][Full Text] [Related]
32. Predicting the future trend of drug-resistant tuberculosis in Thailand: assessing the impact of control strategies. Nishiura H; Patanarapelert K; Tang IM Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):649-56. PubMed ID: 15689082 [TBL] [Abstract][Full Text] [Related]
33. A low cost, home-made, reverse-line blot hybridisation assay for rapid detection of rifampicin resistance in Mycobacterium tuberculosis. Morcillo N; Zumarraga M; Alito A; Dolmann A; Schouls L; Cataldi A; Kremer K; van Soolingen D Int J Tuberc Lung Dis; 2002 Nov; 6(11):959-65. PubMed ID: 12475141 [TBL] [Abstract][Full Text] [Related]
34. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. Jenny-Avital ER; Joseph K Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504 [TBL] [Abstract][Full Text] [Related]
35. Primary drug resistance pattern of mycobacterium tuberculosis in Dhaka, Bangladesh. Miah MR; Ali MS; Saleh AA; Sattar H Bangladesh Med Res Counc Bull; 2000 Aug; 26(2):33-40. PubMed ID: 11508069 [TBL] [Abstract][Full Text] [Related]
36. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Narita M; Stambaugh JJ; Hollender ES; Jones D; Pitchenik AE; Ashkin D Clin Infect Dis; 2000 May; 30(5):779-83. PubMed ID: 10816148 [TBL] [Abstract][Full Text] [Related]
37. [Changes in drug resistance of Mycobacteria in the simultaneous use of chemotherapy and intravenous infusions of dissolved ozone]. Belianin II; Shmelev EI Probl Tuberk Bolezn Legk; 2004; (7):32-5. PubMed ID: 15379039 [TBL] [Abstract][Full Text] [Related]
38. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Dye C; Williams BG; Espinal MA; Raviglione MC Science; 2002 Mar; 295(5562):2042-6. PubMed ID: 11896268 [TBL] [Abstract][Full Text] [Related]
39. Factors associated with treatment success for tuberculosis patients: a single center's experience in Turkey. Talay F; Kumbetli S; Altin S Jpn J Infect Dis; 2008 Jan; 61(1):25-30. PubMed ID: 18219130 [TBL] [Abstract][Full Text] [Related]
40. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T; Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]